Currently, under- or over-diagnosis of cardiovascular disease sometimes results in failure to prevent adverse events or inappropriate interruption of a potentially life-saving anticancer treatment. "We need to be clear when it's a must to stop the treatment, when we should reduce the dose, or when we can continue with the therapy," said Professor Zamorano. "This position paper provides guidance in this area."
Special items: Ovarian Cancer and Us blog best viewed in Firefox
▼
Monday, August 29, 2016
Tackling cardiac toxicity of anticancer therapies
Science news
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.